June 18, 2024 | PMP Series | Prescribing Buprenorphine: What is the Role and Risk of Monoproduct in Maintenance Therapy of Opioid Use Disorder (OUD)? | ME SUD Learning Community

$0.00

Description

June 18, 2024 | 12:00-1:00pm

Description:

Is monoproduct (buprenorphine) truly lower risk than combination (buprenorphine-naloxone) therapy and if so, how much? What should a provider do with patients who report adverse effects of buprenorphine/naloxone? This session will review evidence to understand the risk of monoproduct compared to combination product when used for maintenance of opioid use disorder (OUD). With this evidence as background, we will discuss recommendations for  clinical decisions about prescribing monoproduct for OUD.

Learning Objectives:

  1. Recognize the evidence that characterizes mono versus combination product risk
  2. Describe factors that mitigate risk of buprenorphine misuse and diversion including treatment access, choice of combination vs monoproduct, injectable buprenorphine, clinical monitoring
  3. Articulate indications for monoproduct prescribing and their likely frequency

Presenters:

photo of a woman smiling against a white background

Andrea Truncali, MD MPH

Andrea Truncali, MD, MPH is a board-certified physician in both Internal and Addiction Medicine, and an Assistant Professor of Medicine at Tufts University. She completed medical school and residency at New York University, followed by further training in preventive medicine and public health. In pursuit of improving the health and well-being of underserved people, Dr Truncali takes care of patients in specialty substance use treatment as well as primary care settings, provides education and guidance to physicians on the topic of substance use disorder, and contributes to activities at the state level regarding substance use prevention and treatment.

Stephanie Nichols, PharmD, MPH, BCPP, FCCP

Stephanie Nichols, PharmD, BCPP, MPH is an Associate Professor in the University of New England College of Pharmacy, Adjunct Clinical Assistant Professor of Psychiatry in the Tufts University School of Medicine, and a Psychiatric and Substance Use Disorder (SUD) Pharmacist at Maine Medical Center in Portland. She graduated from the University at Buffalo with her Doctor of Pharmacy degree and completed an Inpatient Pharmacy Practice Residency at Maine Medical Center. Dr. Nichols is dual board certified as a Pharmacotherapy Specialist (BCPS) and a Psychiatric Pharmacist (BCPP) and is a fellow of the American College of Clinical Pharmacy (FCCP).

Audience:
Prescribing clinicians and their teams

Continuing Medical Education
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Maine Medical Education Trust and CCSME. The Maine Medical Education Trust is accredited by the Maine Medical Association Committee on Continuing Medical Education and Accreditation to provide continuing medical education for physicians.

The Maine Medical Education Trust designates this regularly scheduled series for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

*Nurses and Nurse Practitioners will be awarded a certificate of participation with a maximum of 1 AMA PRA Category 1 Credit™.

Contact Hours
1 contact hours for social workers, licensed clinical professional counselors, and behavioral health professionals.
1 Category I contact hours for psychologists. CCSME is a pre-approved sponsor and provider of Professional Education Activities for Psychologists.
1 contact hours for Alcohol and Drug Counselors pending approval by the Maine Board of Alcohol and Drug Counselors
1 contact hours CHES. CCSME is a designated provider of continuing education contact hours (CECH) in health education by the National Commission for Health Education Credentialing, Inc.